Equity Research, Broker Reports, and media content on Oxurion NV

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about Oxurion NV
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Oxurion NV

Company Profile

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on Oxurion NV. We currently have 0 research reports from 0 professional analysts.

Date Source Announcement
06Sep18 16:40 GNW ThromboGenics Business Update - H1 2018
03Sep18 16:40 GNW ThromboGenics becomes "Oxurion"
19Jul18 16:40 GNW ThromboGenics Reports Day 150 Topline Data from its Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for the Treatment of Diabetic Macular Edema (DME)
27Jun18 06:30 GNW ThromboGenics Plans Name Change to "Oxurion"
21Jun18 07:00 GNW ThromboGenics Partners with Prevent Blindness at 2018 Focus on Eye Health National Summit in Washington DC
25May18 06:30 GNW ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149, a plasma kallikrein inhibitor, for treatment of Diabetic Macular Edema (DME)
23May18 07:00 GNW ThromboGenics to present a preclinical overview of its two most advanced diabetic eye disease clinical candidates, THR-317 and THR-149, at EASDec 2018
  • Frequency of research reports

     

  • Research reports on

    Oxurion NV

  • Providers covering

    Oxurion NV